ADAPY (Adaptimmune Therapeutics) Net Margin %: -221.83% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Net Margin %?

Adaptimmune Therapeutics ADAPY +5.80% Net Margin % is -221.83% as of Jun. 2025.

Net margin is calculated as Net Income divided by its Revenue. Adaptimmune Therapeutics's Net Income for the three months ended in Jun. 2025 was $-30.34 Mil. Adaptimmune Therapeutics's Revenue for the three months ended in Jun. 2025 was $13.68 Mil. Therefore, Adaptimmune Therapeutics's net margin for the quarter that ended in Jun. 2025 was -221.83%.

The historical rank and industry rank for Adaptimmune Therapeutics's Net Margin % or its related term are showing as below:


ADAPY's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -77.59
* Ranked among companies with meaningful Net Margin % only.

Adaptimmune Therapeutics  (OTCPK:ADAPY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Adaptimmune Therapeutics Net Margin % Related Terms

Adaptimmune Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Net Margin % Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,286.81 -2,570.99 -609.46 -188.90 -39.78

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.22 -43.07 -2,303.38 -653.18 -221.83

ADAPY vs BCLI, APRE, JSPR: Net Margin % Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Net Margin % falls into.


Adaptimmune Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Adaptimmune Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-70.814/178.032
=-39.78 %

Adaptimmune Therapeutics's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-30.34/13.677
=-221.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -221.83% mean?
Adaptimmune Therapeutics (ADAPY) has a Net Margin % of -221.83% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Net Margin % too high?
Adaptimmune Therapeutics' current Net Margin % is -221.83%.
How does Adaptimmune Therapeutics' Net Margin % compare to BCLI and APRE?
Adaptimmune Therapeutics' Net Margin % of -221.83% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Net Margin % is -221.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Net Margin % of -221.83%. The current Net Margin % is -221.83%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Net Margin % is -221.83% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].